Aplagon doses first patient in phase 2a trial of APAC with peripheral arterial occlusive disease/chronic limb threatening ischemia: Helsinki, Finland Saturday, March 14, 2026, 18: ...

The Departments of Pathology and Pediatrics of Father Muller Medical College successfully conducted HAEM INSIGHT 3.0, a ...

Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia HELSINKI, 12 March 2026 - Aplagon, a ...

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

When we discuss bacterial infections, we often think of exotoxins—those soluble proteins actively secreted by bacteria—while overlooking endotoxins, which are more insidious but equally dangerous.

Aplagon has dosed the first patient in its phase 2a HEALING clinical trial evaluating APAC, a first‑in‑class treatment for thrombo‑inflammatory diseases, in people with peripheral arterial occlusive ...

As a common production contaminant, trace endotoxin triggers immune responses, skews results, and jeopardizes patient safety--risks that are critical in immunology, cell/gene therapy, and vaccine ...

While exotoxins dominate discussions of bacterial infections, endotoxins-cell wall components released upon bacterial death-are equally dangerous. These ...

Cannabis and other illicit drugs are associated with higher stroke risk, underscoring the importance of addressing substance ...

Leerink Global Healthcare Conference 2026 March 11, 2026 9:20 AM EDTCompany ParticipantsJasper Van GrunsvenPeter Griffith - Executive ...

Executives from Amgen (NASDAQ:AMGN) highlighted broad-based commercial growth, a set of six “key growth drivers,” and several late-stage pipeline programs during a conference session hosted by Leerink ...